
Conference Coverage
about 5 hours ago
Employers Weigh More Than Cost in Cancer Care: Karen van Caulil, PhDabout 7 hours ago
COA Findings Counter Payer Assumptions: Stephen "Fred" Divers, MDLatest Content

Surrogate End Points, Drug Costs Complicate Oncology Formularies

91% of Community Oncology Sites Offer Bispecifics Despite Barriers

COVID-19, Measles, and the New Vaccine Order: What Parents Should Know

Switching to Subcutaneous Ocrelizumab for MS Could Free 883 Chair Hours in a Year

Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges

Shorts










Center on Health Equity & Access
All News

Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.

Patients with colorectal or ovarian cancer enrolled in a clinical trial have lower pharmacy and medical costs during the 9 months after trial initiation.

Survey findings show that although physicians view continuous glucose monitoring (CGM) as transformative, systemic barriers persist, leading to variable adoption across clinical practices.

Physicians to Discuss 2026 Oncology Care Index at Patient-Centered Oncology Care®, Premier Annual AJMC® Event Starting Today in Nashville | 60% of Community Physicians Say Clinical Trial Options Are Limited; 93% Say Pragmatic Designs Would Help

Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.

Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.

Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.

“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.

Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.

Medicare's cell and gene therapy payment gap remains, with hospitals absorbing costs as insurers limit coverage.





























